Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer.

ABSTRACT:

Background

Clinical significance of primary tumor progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC) is unclear.

Methods

Clinical data from 987 patients with mHSPC from multiple institutions between September 1999 and November 2023 were reviewed. The prognostic impact of primary tumor progression was examined along with other clinical parameters. Castration-resistant prostate cancer progression-free survival (CRPC PFS) and overall survival (OS) were analyzed as clinical outcomes. Student's t-test, Cox proportional hazards models, and Kaplan-Meier methods were utilized to validate the clinical significance.

Results

The median age and initial prostate-specific antigen (iPSA) values were 74 and 221 ng/ml, respectively. 632 (64%) and 355 (36

SUBMITTER: Yamada Y 

PROVIDER: S-EPMC11979369 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature